ISSN: 2322 - 0902 (P)
ISSN: 2322 - 0910 (O)

International Journal of Ayurveda and Pharma Research

Review Article

ALLERGIC RHINITIS: A CRITICAL MODERN REVIEW

Narender Chanchal[1]*, Smriti Kaul[2], Riju Agrawal[3], Daya Shankar Singh[4]

*[1]Assistant Professor, Department of Shalakya Tantra, Kunwar Shekhar Vijendra Ayurveda Medical College & Research Centre, Shobhit University, Gangoh, Saharanpur, Uttar Pradesh.

[2]MS Scholar, PG Department of Shalakya Tantra, Patanjali Bhartiya Ayurvigyan Evum Anusandhan Sansthan, Haridwar, Uttarakhand, India.

[3]Associate Professor & Head, Dept. of Shalakya Tantra, Ch Brahm Prakash Ayurved Charak Sansthan New Delhi.

[4]Associate Professor, Shalakya Tantra Department, Patanjali Bhartiya Ayurvigyan Evam Anusandhan Santhan, Haridwar, Uttarakhand.

Article info

Article History:

Received: 29-10-2021

Revised: 25-11-2021

Accepted: 22-12-2021

KEYWORDS:

Allergic rhinitis, hypersensitive rhinitis, Local nasal allergy, immunotherapy, SPT, RAST, subcutaneous immunotherapy (SCIT), sublingual immunotherapy (SLIT).

ABSTRACT

Allergic rhinitis addresses a hyperactivity of the resistant framework in any case harmless particles making a fiery reaction where none is required. Allergic Rhinitis is clinically represented by a mixture of two or additional nasal symptoms: running, blocking, itching and sneezing. Allergic rhinitis is regularly partitioned by age, seriousness, and duration of symptoms. Investigation represents how epidemiologic evaluations on the commonness of hypersensitive or allergic rhinitis shift considerably with whether both clinical appraisal and testing were utilized to make the determination. The treatment of allergic rhinitis should combine allergen avoidance, pharmacotherapy and allergen immunotherapy. Treatments of allergic rhinitis include intranasal corticosteroids, oral and topical antihistamines, decongestants, intranasal cromolyn, intranasal anticholinergics. First-generation and Second-generation oral antihistamines and intranasal corticosteroids are the most effective modality for treating allergic rhinitis. Immunotherapy is an efficient immune-modulating treatment that ought to be counseled if pharmacologic medical care for allergic rhinitis isn't effective or not tolerated. This article provides an overview of the prevalence, pathophysiology, diagnosis, and appropriate management of the allergic rhinitis.

INTRODUCTION

Allergic rhinitis addresses a hyperactivity of the resistant framework in any case harmless particles making a fiery reaction where none is required. The aggravation brought about by the natural opening produces side effects including wheezing, tingling, rhinorrhea and nasal blockage. Albeit unfavourably susceptible rhinitis has no critical danger of mortality, the indications considerably affect rest, efficiency and personal satisfaction.

Access this article online

Quick Response Code

https://doi.org/10.47070/ijapr.v10i1.2251

The omnipresence and effect of hypersensitive rhinitis consolidate to make it a significant condition influencing the strength of a huge number of individuals around the world. Unfavourably susceptible rhinitis is a moderately regular issue influencing 10–25% of people in Western societies.[1]

To some extent, in view of its shared characteristic, most experts know about this condition and much of the time it is generally simple to diagnose.[2] Hypersensitive rhinitis is because of the affidavit onto the nasal mucosa of allergens to which the patient has effectively delivered explicit immunoglobulin E (IgE).[3] Unfavourably susceptible rhinitis (AR) is a typical clinical issue, with ongoing assessments of 20% to 40% of the population in the US being affected.[4]

Inhalant allergens are ordinarily delegated occasional, for example, plant dusts, or enduring, like pet dander, cockroach, or residue parasite. Nine percent of the overall US population has asthma, with

around 60% of these people having proof of atopy (for example at least one sure explicit IgE).[5-6] The clinical administration of patients with AR incorporates allergen evasion, pharmacotherapy and immunotherapy. [7]

Definition

Rhinitis is defined clinically by a mixture of 2 or additional nasal symptoms: running, blocking, itching and sneezing. Allergic rhinitis happens once these symptoms are the results of IgE-mediated inflammation following exposure to allergen. The 2008 ARIA (Allergic Rhinitis and its Impact on Asthma) review outlined rhinitis as "a symptomatic disorder of the nose induced when substance exposure by an immune gamma globulin (IgE) inflammation". [8]

Prevalence

Allergic rhinitis is a worldwide medical issue and is expanding in prevalence.[9-10] Ongoing global examinations show wide varieties in predominance utilizing straight forward 'working definitions' in normalized surveys. The international Study of Asthma and Sensitivities in Youth (ISAAC)[11] noticed the pervasiveness of rhinitis with irritated watery eyes, in six to long term olds as 0.8 to 14.9 percent and in long term olds from 1.4 to 39.7 percent in various nations all through the world.

The UK had a high commonness of rhinitis. The general connection between the predominance of asthma and rhinitis in younger students was critical (Sigma= 0.65, p<0.0001). A cross-sectional Swiss study pleasantly delineates issues in surveying the predominance of unfavourably susceptible rhinitis.[12-14]

An aggregate of 9651 adults were assessed with the accompanying inquiries in the SALPADIA (Swiss Study on Air Pollution and Lung Diseases in Adults): Hypersensitive rhinitis was analyzed in 13.5% (females 13%, males 14%. The positive prescient incentive for a SPT was 48.7% and 43.5% for explicit IgE testing. This investigation represents how epidemiologic evaluations on the commonness of hypersensitive or allergic rhinitis shift considerably with whether both clinical appraisal and testing were utilized to make the determination.

Classification of Allergic Rhinitis

Allergic rhinitis is regularly partitioned by age (children vs adults), seriousness (mild, moderate or severe), and duration of symptoms (intermittent or persistent).

Table 1: Allergic Rhinitis and its Impact on Asthma 2008 classification of allergic rhinitis

Duration	Intermittent Persistent	Symptoms are present <4 days a week or <4 consecutive weeks Symptoms are present > 4 days per week and > 4 consecutive weeks
Severity	Mild Moderate/Severe (One or more of the listed effects)	Moderate/severe impairments absent Sleep disturbance, impairment of daily activities, leisure, or sport impairment of school or work troublesome symptoms

Pathology



Fig. 1: Classic pathophysiology of IgE production. Allergen is recognized by antigen presenting cell (APC) and the allergenic peptide presented to a T-cell receptor (TCR) via binding with major histocompatibility receptors (MHC). Costimulation of the APC through Toll-like receptor 4 (TR4) with cluster of differentiation 14 (CD14) may influence the presentation to the T helper 2 lymphocyte (Th2 cell). The Th2 cell will generate proallergic mediators such as interleukin 4 (IL-4). Undifferentiated B cells through a combination of allergenic binding with B-cell receptors, Th2 cytokines, and T cell binding can transform into an IgE producing plasma cell. (Sataloff's Comprehensive Textbook of Otolaryngology Head and Neck Surgery Rhinology/Allergy and Immunology Series Editor: Robert T Sataloff MD DMA FACS).

Inhalant allergens are introduced to the mucosal membranes of the eye and respiration mucosa (nostril and lungs) on debris small sufficient to be suspended in "disturbed" air. Pollens, mold spores, dried dirt mite faeces, desiccated insect parts and mammalian dander are a number of the debris that varies in length from 0.1 to one hundred micrometres. Larger debris has a tendency to deposit within the

nostril while smaller debris to the lung through properties of physics. Proteins at the debris that could stimulate the immune system to provide IgE are taken into consideration as allergenic. The specific sequences that bind IgE at the proteins are referred to as allergic epitopes.

Particles at the mucus membranes stumble upon antigen imparting cells (APCs), which bind allergen proteins with primary histocompatibility complex (MHC) receptors. Each man or woman has precise set of MHC receptors, which are necessary within the immune system's cap potential to discover self- from non-self and dangerous from non-harmful substances. Examples of APCs covered dendritic cells, Langerhans' cells, and macrophages. Recently, there was giant interest to determine position of APCs in regulating inflammation, however classically their position has been taken into consideration to switch the allergen to a regulating T-helper lymphocyte (additionally called a Th lymphocyte or CD4 lymphocyte)[15-16].

Th lymphocytes must also recognize allergens and specific APC signals. In order to help the immune system adapt to different types of infections, Th cells tend to produce different sets of neurotransmitters. This functional transformation includes two main groups, Th1 and Th2. Th1 helps the immune system, especially bacterial infections. Th2 lymphocytes realise mediators that facilitate defeat parasites. Interestingly, the Th2 lymphocytes regulate the sort of inflammation seen in allergic conditions [15-16].

Substance stirred up Th2 lymphocytes release a number of mediators that promote allergic inflammation together with IL, that activates alternative inflammatory cells and chemokines, which primarily recruit inflammatory cells. IL-4, IL-5 (eosinophil activation), associate degree IL-13 are particularly important Th2 cytokines. T-cell receptors are thought to play a very important role in controlling the inflammation [15-16].

Within the presence of IL-4, Th2 cells might once more gift the matter to a B lymphocyte. Complicated sign permits the lymph cell to alter to an immune gamma globulin-producing plasmacyte that produces IgE specific for the allergen at the start encountered by the APC. The organism immune serum globulin is discharged and if liberal to bind with IgE receptors on alternative cells. Several of the cells with roles within the system have IgE receptors that will play a task in regulation; however the high-affinity IgE receptors on effector cells that degranulate (mast cells and basophils) are the foremost to blame for allergic symptoms. [15-16].

Mast cells tend to congregate in animal tissues of the skin, conjunctiva, nose, and respiratory organ wherever allergic responses are observed. Once a susceptible individual is re-exposed to the matter, the allergen will bind on to the immune gamma globulin molecules on the somatic cell and trigger degranulation of preformed mediators (Fig. 2). The degranulation of mast cells releases mediators that cause and promote inflammation. In allergic reactions, aminoalkane and leukotrienes have necessary contributions.[15-16]

Exposure of the nose to amine ends up in immediate rhinorrhea, dilation and congestion, itching, and symptom by binding to histamine (H1) receptors on nerves, tube-shaped structure endothelium, and sleek muscle.[17] Leukotrienes once referred to as the slow reacting substance of anaphylaxis; mediate a delayed reaction part through achievement of inflammatory cells that additionally contributes to symptoms of nasal congestion and secretion of mucus which is produced within the nose. Leukotrienes are synthesized through the arachidonic acid pathway instead of discharged as a preformed intercessor that contributes to the delay.



Fig. 2: Substance triggered somatic cell degranulation, immunoglobulin specific for the allergen is guaranteed to the surface of the mast cells. Once 2 IgE molecules cross link to the allergen on re-exposure, mast cell degranulation is triggered. The granules contain preformed mediators of allergic inflammation resembling amine that quickly manufacture symptoms. (Sataloff's Comprehensive Textbook of Otolaryngology Head and Neck Surgery Rhinology/Allergy and Immunology Series Editor: Robert T Sataloff MD DMA FACS).

The on top of printed pathway of IgE-mediated inflammation is balanced by mechanisms to scale back inflammation that embrace T regulative white blood corpuscles and IL-10 beside the Th1 system. Whether or not the hyper-reactivity to harmless particles that happens in hypersensitivity reaction may operate an excessive amount of "upregulation" or deficient "downregulation" (or both) isn't known. However, current theories on the however matter decrement may fit note will increase in IL-10 and T regulator lymphocyte function among alternative changes [15-16].

Diagnosis

Most allergic rhinitis patients are often diagnosed by a combination of history, examination and SPT or radioallergoabsorbent tests (RAST) for specific IgE. [18]

History taking should be thorough and will be power-assisted by the employment of a questionnaire. Presenting symptoms, symptoms of co-morbidities and general medical history, past history and family history, activity and environmental exposure, dietary history and drug use all ought to be taken into account. The frequency, severity, duration, persistence, irregularity or seasonality of symptoms should be queried. The severity of symptoms and impact on quality of life must be noted. Attainable allergens at work and college should even be documented.

Table 2: Comparison of skin prick tests and blood tests in allergy diagnosis

SPT RAST		
Time for results	Immediate result	Days to weeks
Cost	Cheap	Expensive
Safety	Safe – inhalant only	Very safe
Sensitivity	Sensitive	Slightly less sensitive
Affected by therapy	Yes	No
Other requirements	Training for performance and interpretation	Trained operator and interpreter required

Adapted from Scadding, GK and Lund VJ, 2003. Investigatory Rhinology, London: Taylor and Francis, with permission.

Examination

The patient ought to be checked out usually to assess associate degree obvious external features, similar to an allergic crease or allergic salute. A full ENT examination should then be administered with specific emphasis on the nose. Allergic nasal membrane is typically bilaterally swollen, pale or light-blue in colour, oedematous and coated with watery secretions. Examination of the chest with activity of respiratory organ operate should be carried out wherever there's persistent rhinitis or any suspicion of respiratory disorder or alternative pulmonary disorder. [18]

Skin Testing

Immediate-type allergic reaction skin testing could be a means that of measurement of the presence of allergen-specific immune gamma globulin in patients' skin. It involves exposing dermal mastocyte to little amounts of allergen. If there's allergen-specific IgE certain to the mast cell surface, the mast cells degranulate among minutes and unleash histamine. Aminoalkane binds to native vascular and somatic cell histamine receptors and rapidly triggers local vasodilation, swelling, erythema and itching. This local reaction appears like a typical mosquito bite and is termed a "wheal and flare" reaction.

The Joint Task Force of follow Parameters of the American Academy of asthma allergy and immunology (AAAAI) and therefore the American college of Asthma, allergy and immunology (ACAAI) over that up to seventy puncture skin tests and forty connective tissue (intracutaneous) skin tests for inhalant substances are even for an initial diagnostic evaluation. [19]

One typical panel is shown in Table.3. Totally different devices are used to inject a little quantity of allergen into the cuticle while not going deeper into the dermis and variety of various devices exist for this purpose. When using single puncture devices (i.e. twenty-four hours Brown needle, Greer-pick, Quintest or even a twenty seven gauge hypodermic needle), a drop of substance is 1st placed on the skin.

Table 3: Typical Allergy Skin Testing Sheet

Allergen	Percutaneous	Intradermal (1/100 dilution)	Intradermal (1/10 dilution)
Date			
Tree mix			
Grass mix			
Weed mix			
English plantain			
Ragweed mix			

Dust mite
Feathers
Cat dander
Dog dander
Cockroach
Mold spore mix #1
Mold spore mix #2
Mold spore mix #3
Mouse dander
Buffer negative control
Histamine positive control

Percutaneous tests recorded on a scale, 0-4+. Intradermal tests recorded as maximum wheal diameter/maximum flare diameter (e.g. 10mm/ 25mm)

Intradermal (intracutaneous) skin testing: Intracutaneous skin testing is additional sensitive than transdermal skin testing and might be used to detect lesser degrees of allergic reactivity.[19]

Allergy Blood Testing: There are a variety of blood allergic reaction tests that may live blood serum levels of substance-specific IgE in allergic rhinitis.[20-21] The primary commercially out there test was a immunochemical assay termed RAST (from Radio Allergo sorbent Test). Presently available tests not use radioactive tracers however the tests are still cited generically, though inaccurately as "RAST tests." There are currently 3 commercially available blood allergy tests generally use (Immunocap, Immulite, and HYTEC-288), all of that use some kind of allergen absolute to a solid section and a protein or fluorescent detection system.[20]

Management

Management of allergic rhinitis includes substance avoidance, pharmacotherapy, education and probably immunotherapy. Surgery is rarely needed.

Allergen Avoidance and Environmental Control

Avoidance methods are often divided into primary measures which will stop sickness and secondary measures that may ameliorate established disease.

Primary Prevention

Early use of antibiotics with alteration within the gut flora and enlarged vaccinations in babyhood are concerned as potential causative factors in the increasing prevalence of allergic diseases. However, data is presently insufficient to form firm recommendations.[22] Similarly, restrictions of substance exposure to inhalant allergens and extremely allergenic foods throughout adolescence have been suggested. However, these strategies, at best, have resulted in the delay of onset of atopic sensitization and more studies are required. [23]

Secondary Prevention

Exposure to Allergens

Allergens represent major provocative factors in allergic rhinitis in atopic, exposed and allergic individuals. Major indoor allergens embrace house dirt mite, domestic pets, dictyopterous insect and moulds. Seasonal rhinitis results from exposure to pollens that vary keen about earth science and time of year.

Medical Therapy

Of the varied treatment modalities for allergic rhinitis, pharmacotherapy is that the most up-to-date addition to clinical applies with the primary use of antihistamines within the 1940s.[24] The appearance of various medication choices for AR over the past seventy years has light-emitting diode to a large variation in treatment regimens that dissent by patient-specific symptom quality, location and severity. (Table-4)

Table 4: Overview of Pharmacotherapy Options for Allergic Rhinitis

Class	Subclass or route	Representative	Nasal symptom relief	Benefits	Limitations/ adverse effects/ precautions
Antihistamines*	First generation (oral)	Chlorpheniramine Diphenhydramine Hydroxyzine	Sneezing, pruritus, rhinorrhea, +/−congestion	Quick onset, effective	CNS: Sedation, cognitive impairment anticholinergic side effects
	Second generation (oral)	Cetirizine Desloratadine Fexofenadine Levocetirizine Loratadine	Sneezing, pruritus, rhinorrhea, +/− congestion	Effective, long acting, well-tolerated, quick onset	Possible sedation

	Intranasal	Azelastine Olopatadine	Sneezing, pruritus, rhinorrhea, congestion	Quick onset, effective, also helps congestion	Taste, Cost
Corticosteroids*	Intranasal	Budesonide Beclomethasone dipropionate Ciclesonide Flunisolide Fluticasone propionate Fluticasone furoate Mometasone furoate Triamcinolone	Sneezing, pruritus, rhinorrhea, congestion	Effective	Slow onset, local irritation, epistaxis, avoid in patients with glaucoma and cataract
	Oral	Methylprednisolone Prednisone		Quick onset, effective	Systemic adverse effects/risks with long-term use, rare serious risks in short term
Leukotriene modifier	Receptor agonist (oral)	Montelukast	Sneezing, pruritus, rhinorrhea, congestion	Indicated for asthma	Efficacy < first line medications
Decongestants	Intranasal	Oxymetazoline Phenylephrine	Congestion, rhinorrhea	Quick onset, effective	Rhinitis medicamentosa, nasal dryness, elevated blood pressure
	Oral	Pseudoephedrine			Elevated blood pressure, nasal dryness
Mast cell stabilizer	Intranasal	Cromolyn	Sneezing, pruritus, rhinorrhea, congestion	Prevent onset	QID dosing, efficacy < first line medications
Anticholinergic	Intranasal	Ipratropium	Rhinorrhea	Quick onset, effective	Only effects rhinorrhea
Expectorant	Oral	Guaifenesin	Thick secretions	Quick onset, effective	Only works as an expectorant

Antihistamines

Antihistamines block the binding of aminoalkane to the H1 histamine receptor that's concerned within the early section of the allergic reaction. Aminoalkane discharged by mast cells among nasal mucous membrane binds to glandular, neurogenic and tube-shaped structure target cells that cause pruritus, sneezing, rhinorrhea and congestion. Antihistamines are safe and effective for episodic management since they need a brief onset of action, or as a precautions taken on a day to day for persistent symptoms.[25]

The most important improvement of those medications include less permeableness to the blood–brain barrier and therefore reduced central nervous system facet effects, with maybe the exception of cetirizine, which might still cross the blood– brain barrier and cause sedation in an exceedingly dose-dependent manner[26].

Corticosteroids

Corticosteroids are anti-inflammatory drug medications that are thought to down regulate immune responses in allergic rhinitis and reduce mediators within the late part of the allergic reaction. Steroids are lipid soluble and bind to cytoplasmatic receptors that are then transported to the nucleus to result transcription of immune molecules that down regulate the inflammatory response.

Each the anti-inflammatory properties and therefore the adverse effects of corticosteroids are dose dependent, requiring clinical observation of patients who have general or semi-permanent exposure with higher dosing. Oral corticosteroids have

larger efficiency than topical steroids and should give relief of nasal allergic reaction symptoms however should be restricted in long-run use for allergic rhinitis because of facet effects and potential complications related to their use.[25]

Intranasal corticosteroids have the best effectiveness at relieving all primary nasal symptoms of allergic rhinitis and are thought-about a first-line treatment for allergic rhinitis. [25,27] though intranasal corticosteroids are effective for AR and function a first-line treatment, their slow onset of action needs daily use to attain supreme effectiveness.[28]

Decongestants

Nasal decongestants are helpful for treatment of nasal congestion till the underlying acute method resolves or another acceptable semi-permanent treatment choice is instituted or becomes effective. Decongestant medications stimulate adrenergic receptors, leading to constriction within the nasal membrane those results in a fast decrease in swelling and patency of the nasal cavities.

Topical decongestants, like oxymetazoline and adrenergic directly stimulate sympathetic alpha receptors in the nasal mucosa, resulting in rapid relief of nasal congestion and rhinorrhea. Oral decongestants (e.g. pseudoephedrine) stimulate each alpha- and beta-adrenergic receptor, leading to further risks and facet effects with general absorption. Adverse effects of palpitations, irritability, nasal dryness, hypertension, urinary retention, dizziness and cardiac arrhythmia could also be seen with short-run use of systemic decongestants.

Their use is contraindicated in patients with hypertension, closed-angle glaucoma, hyper-thyroidism, vessel diseases, urinary retention and neural structure disease. The drying of the nasal cavity is typically a lot of important within the winter months once there's less humidity in heat-conditioned environments. Long-run decongestant use is usually be limited by adverse effects.[25]

Expectorants

Normal functioning of the nasal airway epithelial tissue needs mucous secretion for mucociliary clearance of particulates, allergens and microorganism from the sinonasal passages. Raised consistency of the secretion will cause stasis of immunogenic particulates that contribute to the inflammatory response in AR. Expectorants comparable to guaifenesin are thought to decrease mucous viscosity and permit for improved mucociliary clearance.

Though not Food and Drug Administration approved for rhinitis, patients with difficulty clearing thick secretions might have the benefit of use of expectorants.[29] Nasal saline irrigations are shown to produce vital symptom relief while not significant facet effects.[30] Nasal saline works by direct dilution and clearance of secretion and hypersensitivity reaction particles from the nasal mucous membrane.

Leukotriene Modifiers

Leukotrienes are inflammatory mediators discharged from white blood cells that partake within the allergic pathway early- and late-phase response and have important contribution to the pathological process of asthma attack by inflicting broncho-constriction and mucous secretion in the lungs. Leukotriene D4 receptor antagonists such montelukast and zafirlukast block leukotriene D4, that reduces the inflammatory response in nasal tissue.

Montelukast has indications for each the treatment of allergic rhinitis and asthma, whereas zafirlukast is only indicated for the treatment of asthma. Comparison of leukotriene receptor antagonists to oral antihistamines and intranasal corticosteroids has shown inferior effectiveness for leukotriene receptor antagonists creating them a second-line treatment. However, they'll enhance the results of alternative treatments for AR.[25,31]

Anticholinergics

Anticholinergic medications decrease parasympathetic tone, which ends up in less secretion of mucous from organ membrane and fewer watery symptoms in patients with rhinitis.[25] 44 Ipratropium, the only on the market topical intra nasal anticholinergic spray, is commonly used for nonallergic vasomotor rhinitis to decrease mucous secretion.

Cromolyns

Cromolyns are mast-cell stabilizers that block the acute part reaction by preventing mastocyte degranulation and release of histamine. Intranasal cromolyns are offered over the counter and have a wonderful safety profile. Cromolyns need continuous use since they're primarily effective at preventing the allergic response instead of obstruction the cascade once mast cell degranulation has occurred. The inferior efficaciousness of cromolyns compared with alternative first-line medications for allergic rhinitis.[32]

Immunotherapy

Allergen immunotherapy involves the perennial administration of associate degree allergen extract so as to induce a state of immunologic tolerance, with a discount in clinical symptoms and necessities for medication throughout sequent natural allergen exposure.[33] Allergen immunotherapy is indicated in those patients with allergic rhinitis with severe symptoms who fail to reply adequately to usual treatment with antihistamines and topical nasal corticosteroids. Allergen SIT is another treatment option. SIT involves controlled, recurrent allergen administration over a amount of your time to desensitize the allergic patient with the goal of

decreasing symptoms. Currently, the utilization of SIT isn't suggested for clinical treatment of IgE-mediated food allergies, and if performed ought to be in an exceedingly extremely controlled setting.[34]

There are 2 kinds of SIT that are presently being employed within the U.S. Subcutaneous immunotherapy (SCIT) for the treatment of seasonal and perennial allergic rhinitis and allergic respiratory disorder has been practiced for many years in the United States. A patient receives frequent subcutaneous injections of an allergen extract, in increasing doses, in an endeavour to enhance allergic symptoms by gradual modification of the allergic response. However, in recent years, there has been interest in exploitation of sublingual immunotherapy (SLIT) as a possible various to SCIT. SLIT involves placement of the substance beneath the tongue for native absorption to desensitize the allergic individual as critical injection. Like SCIT, SLIT desensitization also takes place over a amount of months to years and diminishes allergic symptoms.

CONCLUSION

Allergic rhinitis may be a common problem that's typically straightforward to diagnose and treat. Analysis ought to be directed toward 2 major aims: distinctive the allergens inflicting the matter and considering alternative disorders within the differential diagnosing. Skin and serological testing are complementary strategies of diagnostic evaluation. Immediate hypersensitivity skin testing is a fast and safe methodology for determining the identity of clinically relevant allergens.

Allergic reaction blood testing may be helpful for identifying relevant allergens insure situations. Once performed properly, the right evaluation and diagnosis of rhinitis can facilitate the establishment of applicable and effective therapeutic measures, as well as medication, environmental management measures and allergic immunotherapy. Pharmacotherapy is one amongst the 3 pillars of treatment for AR.

Intranasal corticosteroids and antihistamines are first-line treatments with established efficaciousness and favor in a position safety profiles. Combination therapy is commonly accustomed target each early-phase and late-phase responses for optimum relief, additionally to refractory or severe symptoms that need multimodality therapy. Emerging therapies are directed as specific pathways within the allergic response supply promise to addressing gaps in treatment and continuing symptoms despite supreme pharmacologic therapy.

REFERENCES

1. Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol. 2010; 125 (2 Suppl 2): S103-15.
2. Gendo K. Evidence-based diagnostic strategies for evaluating suspected allergic rhinitis. Ann Intern Med 2004; 140: 278-89.
3. Researcher WR. Mucosal brush biopsy testing of the inferior turbinate to detect local, antigen-specific immunoglobulin E. Int Forum Allergy Rh. 2012; 2(1): 69-74.
4. Salo PM, Calatroni A, Gergen PJ, et al. Allergy-related outcomes in relation to serum IgE: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol. 2011; 127: 1226-35.
5. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma—Summary Report 2007. J Allergy Clin Immunol. 2007; 120 (5 Suppl): S94-138.
6. Gergen PJ, Arbes SJ, Jr Calatroni A, et al. Total IgE levels and asthma prevalence in the US population: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol. 2009; 124: 447-53.
7. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126: 466-76.
8. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA (2)LEN and Aller Gen). Allergy. 2008; 63 (Suppl 86): 8-160.
9. Aberg N, Hesselmar B, Aberg B, Eriksson B. Increase of asthma, allergic rhinitis and eczema in Swedish schoolchildren between 1979 and 1991. Clinical and Experimental Allergy. 1995; 25: 815–9.
10. Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and allergic rhinitis comorbidity. Journal of Allergy and Clinical Immunology. 2000; 106: S201–5.
11. Strachan D, Sibbald B, Weiland S, Ait-Khaled N, Anabwani G, Anderson HR et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatric Allergy and Immunology. 1997; 8: 161–76
12. Kaiser R, Schindler C, Kunzli N, et al. Use of transition probabilities to estimate the effect of smoking on the duration of episodes of respiratory symptoms in diary data: the Swiss Study on Air Pollution and Lung Diseases in Adults (SAPALDIA). Am J Epidemiol. 1998; 148(6): 600-8.
13. Tschopp JM, Sistek D, Schindler C, et al. Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study.

Swiss Study on Air Pollution and Lung Diseases in Adults. Allergy. 1998; 53(6): 608-13.
14. Monn C, Brandli O, Schindler C, et al. Personal exposure to nitrogen dioxide in Switzerland. SAPALDIA team. Swiss Study on Air Pollution and Lung Diseases in Adults. Sci Total Environ. 1998; 215(3): 243-51.
15. Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med. 2001; 344(1): 30-7.
16. Kay AB. Allergy and allergic diseases. Second of two parts. N Engl J Med. 2001; 344(2): 109-13
17. Lieberman P. The basics of histamine biology. Ann Allergy Asthma Immunol. 2011; 106 (2 Suppl): S2-5
18. Bousquet J, van Cauwenberge P, Khaltaev N. Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. Journal of Allergy and Clinical Immunology. 2001; 108: S147–334.
19. Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008; 100 (3 Suppl 3): S1-148.
20. Hamilton RG, Williams PB. Specific IgE Testing Task Force of the American Academy of Allergy A, Immunology, American College of Allergy A, Immunology. Human IgE antibody serology: a primer for the practicing North American allergist/immunologist. J Allergy Clin Immunol. 2010; 126(1): 33-8.
21. Grammer L. Patterson's Allergic Disease: Philadelphia, PA: Lippincott; 2009.
22. Gore C, Custovic A. Can we prevent allergy? Allergy. 2004; 59: 151–61.
23. Arshad SH, Matthews S, Gant C, Hide DW. Prevention of atopic disease in children. Lancet. 1992; 339: 1493–7
24. Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011; 128: 1139-50.
25. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practiceparameter. J Allergy Clin Immunol. 2008; 122: S1-84.
26. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol. 2003; 111: S835-42.
27. Benninger M, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol. 2010; 104: 13-29.
28. Blaiss MS. Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc. 2011; 32: 413-8
29. Storms W, Farrar JR. Guaifenesin in rhinitis. Curr Allergy Asthma Rep. 2009; 9: 101-6.
30. Hermelingmeier KE, Weber RK, Hellmich M, et al. Nasal irrigation as an adjunctive treatment in allergic rhinitis: a systematic review and meta-analysis. Am J Rhinol Allergy. 2012; 26: e119-25.
31. Simon RA. The role of leukotrienes and anti-leukotriene agents in the pathogenesis and treatment of allergic rhinitis. Clin Rev Allergy Immunol. 1999; 17: 271-5.
32. Welsh PW, Stricker WE, Chu CP, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc. 1987; 62: 125-34.
33. Bousquet J, Lockey R, Malling HJ, Alverez-Cuesta E, Canonica GW, Chapman MD et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. Annals of Allergy, Asthma and Immunology. 1998; 81: 401–5.
34. Boyce JA, Assa'ad A, Burks WA, et al. Guidelines for the diagnosis and management of food allergy in the United States: Report of the NIAID-Sponsored Expert Panel. J Allergy Clin Immunol. 2010; 126: S1-S58.

Cite this article as:
Narender Chanchal, Riju Agrawal, Daya Shankar Singh, Munna Kumar, Jayvindra Singh. Allergic Rhinitis: A Critical Modern Review. International Journal of Ayurveda and Pharma Research. 2022;10(1):78-86.
https://doi.org/10.47070/ijapr.v10i1.2251
Source of support: Nil, Conflict of interest: None Declared

***Address for correspondence**
Dr. Narender Chanchal
Assistant Professor,
Department of Shalakya Tantra,
Kunwar Shekhar Vijendra Ayurveda Medical College & Research Centre,
Shobhit University, Gangoh, Saharanpur,
Uttar Pradesh.
Email:
drnarenderchanchal02051993@gmail.com
Ph: 8219475089